drugset / Trial / NCT01342796
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
RandomizedParallel-groupSingle-blindPrevention
Summary
This study aims to evaluate the immunogenicity, by means of cell mediated immunity (CMI) and hemagglutination inhibition (HI) assay, and also the safety of a MF59C.1-adjuvanted subunit influenza vaccine compared with a conventional subunit vaccine in previously unvaccinated children aged 6 to \<36 months.
Timeline
- Start
- 2011-05
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MF59C.1-adjuvanted subunit influenza vaccine | Vaccine | 0.25 ml | Intramuscular |
| Comparator | Sub unit, Inactivated, Influenza vaccine | Vaccine | 0.25 ml | Intramuscular |